Compare Dishman Pharma with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs WYETH - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA WYETH DISHMAN PHARMA/
WYETH
 
P/E (TTM) x 25.1 27.7 90.5% View Chart
P/BV x 3.3 5.3 62.6% View Chart
Dividend Yield % 0.7 1.3 52.2%  

Financials

 DISHMAN PHARMA   WYETH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
WYETH
Mar-13
DISHMAN PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs3741,044 35.8%   
Low Rs129818 15.8%   
Sales per share (Unadj.) Rs197.8298.6 66.3%  
Earnings per share (Unadj.) Rs21.257.2 37.0%  
Cash flow per share (Unadj.) Rs34.758.4 59.4%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.81.8 43.5%  
Book value per share (Unadj.) Rs179.9249.5 72.1%  
Shares outstanding (eoy) m80.6922.72 355.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.1 40.8%   
Avg P/E ratio x11.916.3 72.9%  
P/CF ratio (eoy) x7.215.9 45.5%  
Price / Book Value ratio x1.43.7 37.5%  
Dividend payout %9.429.7 31.8%   
Avg Mkt Cap Rs m20,30621,157 96.0%   
No. of employees `0000.80.5 168.5%   
Total wages/salary Rs m5,355400 1,338.7%   
Avg. sales/employee Rs Th19,252.713,787.4 139.6%   
Avg. wages/employee Rs Th6,459.5813.0 794.5%   
Avg. net profit/employee Rs Th2,064.12,643.3 78.1%   
INCOME DATA
Net Sales Rs m15,9616,783 235.3%  
Other income Rs m265353 75.3%   
Total revenues Rs m16,2267,136 227.4%   
Gross profit Rs m4,1031,617 253.7%  
Depreciation Rs m1,09127 4,100.0%   
Interest Rs m9446 17,170.9%   
Profit before tax Rs m2,3341,938 120.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m624632 98.6%   
Profit after tax Rs m1,7111,301 131.6%  
Gross profit margin %25.723.8 107.8%  
Effective tax rate %26.732.6 81.9%   
Net profit margin %10.719.2 55.9%  
BALANCE SHEET DATA
Current assets Rs m11,0186,984 157.8%   
Current liabilities Rs m9,5172,056 462.9%   
Net working cap to sales %9.472.6 12.9%  
Current ratio x1.23.4 34.1%  
Inventory Days Days11099 111.3%  
Debtors Days Days3524 145.5%  
Net fixed assets Rs m16,304244 6,673.8%   
Share capital Rs m161227 71.0%   
"Free" reserves Rs m12,9075,441 237.2%   
Net worth Rs m14,5165,668 256.1%   
Long term debt Rs m4,18925 16,757.6%   
Total assets Rs m29,8057,901 377.2%  
Interest coverage x3.5353.3 1.0%   
Debt to equity ratio x0.30 6,543.5%  
Sales to assets ratio x0.50.9 62.4%   
Return on assets %8.916.5 53.9%  
Return on equity %11.822.9 51.4%  
Return on capital %17.534.0 51.5%  
Exports to sales %24.80.2 11,361.0%   
Imports to sales %3.736.3 10.3%   
Exports (fob) Rs m3,95615 26,731.1%   
Imports (cif) Rs m5962,465 24.2%   
Fx inflow Rs m4,95215 32,575.7%   
Fx outflow Rs m6972,677 26.0%   
Net fx Rs m4,255-2,662 -159.8%   
CASH FLOW
From Operations Rs m2,786923 301.8%  
From Investments Rs m-1,529317 -482.5%  
From Financial Activity Rs m-941-481 195.7%  
Net Cashflow Rs m316759 41.7%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 3.7 11.3 32.7%  
FIIs % 12.7 7.2 176.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 30.4 72.7%  
Shareholders   46,261 21,978 210.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS